Patrick Ward, MD
Hematology & Oncology · Cincinnati, OHNPI 1093709297
Payments from drug & device makers
Across 1,179 payments — averaging $3258.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1.1M
- E.r. Squibb & Sons, L.L.C.$629K
- Eli Lilly$512K
- Seagen Inc.$366K
- Genentech, Inc.$360K
- Mirati Therapeutics, Inc.$224K
- plus $610K from 29 others
Across 51 payments — averaging $548.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Scientific Affairs, LLC$25K
- Eli Lilly$2K
- Pfizer$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 30 | $1,141,001 |
| E.r. Squibb & Sons, L.L.C. | 43 | $629,320 |
| Eli Lilly | 33 | $512,026 |
| Seagen Inc. | 291 | $365,715 |
| Genentech, Inc. | 116 | $360,081 |
| Mirati Therapeutics, Inc. | 107 | $223,698 |
| Merck | 227 | $197,520 |
| AstraZeneca | 18 | $128,279 |
| Pfizer | 83 | $69,371 |
| Janssen Research & Development, LLC | 37 | $68,214 |
| Daiichi Sankyo Inc. | 33 | $49,876 |
| Novartis | 14 | $45,951 |
| F. Hoffmann-la Roche AG | 3 | $12,500 |
| AbbVie | 16 | $11,565 |
| Janssen Scientific Affairs, LLC | 85 | $7,017 |
| Tesaro, Inc. | 4 | $5,910 |
| GSK | 1 | $3,123 |
| Boehringer Ingelheim | 1 | $3,010 |
| Incyte Corporation | 4 | $2,882 |
| Fresenius Kabi USA, LLC | 1 | $2,200 |
| Avyxa Pharma, LLC | 1 | $1,000 |
| Johnson & Johnson | 7 | $635 |
| Genentech USA, Inc. | 4 | $243 |
| EMD Serono, Inc. | 1 | $122 |
| Gilead | 5 | $98 |
| Myovant Sciences Inc. | 1 | $95 |
| AVEO Pharmaceuticals, Inc. | 3 | $85 |
| Amneal Pharmaceuticals LLC | 2 | $36 |
| Lilly USA, LLC | 2 | $35 |
| G1 Therapeutics, Inc. | 1 | $29 |
| Eisai Inc. | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $14 |
| Bayer | 1 | $13 |
How this compares
$3,841,713 in reported general payments places this provider in the 95th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Cincinnati
- Trisha Wise-DraperCincinnati$9.8M
- Davendra SohalCincinnati$8.6M
- David WaterhouseCincinnati$5.7M
- James EssellCincinnati$3.7M
- Edward FaberCincinnati$2.3M
- Omar AlkharabshehCincinnati$1.2M
- Alexander StarodubCincinnati$1.1M
- Mark JohnsCincinnati$999K
- Jason JonesCincinnati$948K
- Shuchi GulatiCincinnati$792K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.